Journal of Neuro-Oncology最新文献

{"title":"Residual tumor volume guides post-surgical treatment paradigm and need for salvage radiotherapy in vestibular schwannoma management.","authors":"Ansley Unterberger, Alex Devarajan, Jack Zhang, Emery Monnig, Akhil Rao, Mehek Dedhia, George Wanna, Joshua Bederson, Raj Shrivastava","doi":"10.1007/s11060-026-05603-6","DOIUrl":"https://doi.org/10.1007/s11060-026-05603-6","url":null,"abstract":"<p><strong>Background and objectives: </strong>Vestibular schwannomas (VS) are slow-growing tumors of the vestibular nerve. Gross total resection (GTR) is recommended for large tumors (> 4 cm), brainstem compression, cranial neuropathy, and hydrocephalus. In select complex cases at our high-volume skull base center, subtotal resection (STR) is pursued for various clinical factors. These patients may require adjuvant radiotherapy (ART) if residual tumor progresses. We sought to evaluate tumor control following STR of VS and identify risk factors of future ART need.</p><p><strong>Methods: </strong>A single-center retrospective review (2009-2019) identified patients with VS with complete data who underwent STR without prior treatment. Tumor volumes were extracted from contrast-enhanced T1-weighted volumetric MRI by semi-automated segmentation using 3D Slicer. Clinical and procedural data, including House-Brackmann scores at discharge and 90-day follow-up, were reviewed. Postoperative tumor volumes and progression-free survival (PFS) were calculated. Multivariate logistic regression assessed risk factors for ART.</p><p><strong>Results: </strong>Among 1119 VS patients, 38 (3.4%) patients underwent STR. Of the STR patients, 15 (39.5%) required ART. Preoperative volumes did not differ significantly. In STR-alone patients, the average residual volume was 15.26 ± 3.54%, while in STR + ART patients the average residual volume was 37.53 ± 12.33% (p < 0.001). The smallest residual requiring ART was 23.4%, while the largest residual not requiring ART was 20.6%. Median PFS among ART patients was 29.67 months. On multivariate analysis, percent residual volume independently predicted ART need (AOR 1.28, CI 1.06-2.29, p = 0.002).</p><p><strong>Conclusion: </strong>STR is viable in select complex VS cases. Residual VS volume ≥ 20.6% may confer increased risk of progression and necessitate ART. Close postoperative surveillance over 2-3 years is warranted.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of distance in treating glioblastoma: a retrospective single-center study.","authors":"Samantha Mohl, Samuel A Tenhoeve, Scott King, Yuxin Zhao, Y Ann Chen, Joe Mendez, Rachna Malani","doi":"10.1007/s11060-026-05596-2","DOIUrl":"https://doi.org/10.1007/s11060-026-05596-2","url":null,"abstract":"<p><strong>Purpose: </strong>Glioblastoma (GBM) is an aggressive primary brain tumor with poor overall survival. Patients living in rural areas have worse outcomes than those in metropolitan regions, but the effect of distance from subspecialty care on survival and clinical trial participation remains unclear. We evaluated the association between distance to a National Cancer Institute-designated Comprehensive Cancer Center (CCC) and overall survival (OS) and clinical trial enrollment in patients with isocitrate dehydrogenase wild-type GBM.</p><p><strong>Methods: </strong>We retrospectively identified patients with newly diagnosed isocitrate dehydrogenase wild-type GBM (2021 World Health Organization classification) who received treatment at our CCC (2018-2022). Distance from the CCC was analyzed as both categorical and continuous variables. Univariable and multivariable Cox regression models were performed, adjusting for established prognostic factors.</p><p><strong>Results: </strong>The 167 patients had similar baseline characteristics across distance groups. In univariable analyses, no significant difference in OS was observed between patients living near the CCC and those at intermediate or far distances. In multivariable analysis, patients in the intermediate-distance group demonstrated significantly worse OS compared with the near group (hazard ratio 1.61, 95% confidence interval 1.03, 2.50, p = 0.035). Increasing distance was associated with significantly lower clinical trial enrollment (near 43%, intermediate 35%, and far 18%; p = 0.0001).</p><p><strong>Conclusions: </strong>Distance from a CCC was associated with disparities in survival and access to clinical trials among patients with isocitrate dehydrogenase wild-type GBM. Given that clinical trials represent a standard-of-care option for GBM, strategies to improve access to subspecialty care and trial participation are needed to reduce outcome disparities.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns and survival outcomes in neuroendocrine neoplasms presenting with brain metastases.","authors":"Zouina Sarfraz, Tulika Ranjan, Fatma Nihan Akkoc Mustafayev, Joey Luzarraga, Lydia Hodgson, Manmeet S Ahluwalia","doi":"10.1007/s11060-026-05529-z","DOIUrl":"https://doi.org/10.1007/s11060-026-05529-z","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes.","authors":"Shailen G Sampath, Anthony J Tang, Alan X Chen, Ashwin Viswanathan, Chiemela Izima, Alex H Manriquez, Nicholas B Dadario, Nathan Winans, Misha Amini, Nathaniel Rolfe, Arjun R Adapa, Michael G Argenziano, Colin P Sperring, Justin A Neira, Liang Lei, Peter Canoll, Jeffrey N Bruce","doi":"10.1007/s11060-026-05601-8","DOIUrl":"https://doi.org/10.1007/s11060-026-05601-8","url":null,"abstract":"<p><strong>Background/purpose: </strong>Glioblastoma (GBM) is characterized by an immunosuppressive tumor microenvironment and poor responsiveness to immune checkpoint blockade, driving interest in cGAS-STING pathway activation to stimulate antitumor immunity. We performed a systematic review of preclinical in vivo studies evaluating STING agonists in glioblastoma, with emphasis on immune microenvironment effects and survival outcomes.</p><p><strong>Methods: </strong>A systematic review of PubMed, Cochrane, and Embase was conducted through February 2025 following PRISMA guidelines. Studies were included if they evaluated STING agonists in live animal models of GBM and reported survival outcomes or tumor microenvironment changes. Two reviewers independently screened studies and extracted data. Risk of bias was assessed qualitatively based on study design and reporting characteristics. Given heterogeneity in models, treatments, and outcomes, results were synthesized descriptively.</p><p><strong>Results: </strong>Fourteen studies met the inclusion criteria, spanning synthetic and natural cyclic dinucleotides and non-cyclic STING agonists. Across diverse delivery methods, including intracranial injection, hydrogels, and nanoparticle systems, STING agonists were associated with increased CD8 + T-cell and NK cell infiltration and repolarization of tumor-associated macrophages toward pro-inflammatory phenotypes. Several studies reported prolonged survival, including long-term tumor clearance in select models. Combination therapies with immune checkpoint inhibitors or radiotherapy showed synergistic effects in some studies.</p><p><strong>Conclusions: </strong>STING agonists can enhance anti-tumor immune responses and prolong survival in preclinical GBM models by promoting cytotoxic lymphocyte recruitment and remodeling the tumor-associated myeloid landscape. However, translation remains challenging due to limitations of current models, the limited clinical traction STING modulation has thus far achieved in other cancer types, incomplete understanding of cell-type-specific STING activation in the brain, and the possibility that sustained STING signaling may drive maladaptive inflammation rather than durable antitumor immunity.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virus-like particle vaccine targeting meningeal lymphatic vessels via intradural delivery activates anti-glioma immunity.","authors":"Minglu Li, Jiang Zhu, Rong Huang, Xiang Yao, Feng Wei, E Chen, Xinhua Tian, Xiaoning Lin","doi":"10.1007/s11060-026-05559-7","DOIUrl":"https://doi.org/10.1007/s11060-026-05559-7","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Redefining the therapeutic landscape of glioblastomas and brain metastasis through cesium brachytherapy and low-kV intra-operative radiation therapy (IORT).","authors":"Carlin Chuck, Abigail Teshome, Alice Lin, Sumaiya Sayeed, Elaina Wang, Natalie Amaral-Nieves, Mazen Taman, Joseph Oldam, Hsien-Chung Chen, Brijal Desai, Andrew Kopecky, Mark J Rivard, Sasmit Sarangi, Heinrich Elinzano, Eric T Wong, Christopher P Cifarelli, Clark C Chen","doi":"10.1007/s11060-026-05593-5","DOIUrl":"https://doi.org/10.1007/s11060-026-05593-5","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of upfront HA-WBRT vs. SRS for treatment of brain metastases due to SCLC.","authors":"Keshav Goel, Yushen Qian, Erqi Pollom","doi":"10.1007/s11060-026-05505-7","DOIUrl":"https://doi.org/10.1007/s11060-026-05505-7","url":null,"abstract":"<p><strong>Introduction: </strong>Hippocampal-avoidant whole brain radiation therapy (HA-WBRT) and stereotactic radio surgery (SRS) are standard of care treatments for brain metastases (BM). However, the optimal approach for treating BM originating from small cell lung cancer (SCLC) remains uncertain. We conducted a cost-effectiveness analysis comparing HA-WBRT and SRS for SCLC BMs.</p><p><strong>Methods: </strong>We constructed a Markov model to evaluate the incremental cost-effectiveness ratio (ICER) of SRS versus HA-WBRT. In this model, patients either receive upfront SRS or HA-WBRT. Those receiving SRS may undergo salvage HA-WBRT if they experience salvageable distant recurrences, or progress to non-salvageable local and distant recurrences. We performed over 100,000 Monte Carlo simulations, varying cost and utility parameters using Beta distributions, to analyze the impact of these variations on the ICER.</p><p><strong>Results: </strong>The base case ICER for SRS was $2126.88. SRS was more costly and more/less effective in 56.1%/43.9% of Monte Carlo simulations. MRI cost had the greatest positive impact on ICER, and cost of hospice had greatest negative impact. The utility decline of the four-month of neurocognitive decline post-HA-WBRT had the strongest negative impact. The transition probabilities of the controlled state, death, distant recurrence (salvageable), and local recurrence (non-salvageable) had statistically significant impacts on ICER (p < 0.001).</p><p><strong>Discussion: </strong>SRS was more expensive than HA-WBRT in all simulations and more effective in most. The cost of the MRI and hospice care and the transition probabilities of the controlled state and death had the greatest influence on ICER. As survival increased, ICER decreased, emphasizing the importance of patient selection for SRS.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subtype-specific prognostic impact of TNIK in medulloblastoma.","authors":"Franz-Leonard Klaus, Theoni Maragkou, Claire Delbridge, Charles G Eberhardt, Ekkehard Hewer, Antonia Gocke, Ramin Radpour, Christian Mawrin, Carolin Mogler, Julia E Neumann, Stefan Forster","doi":"10.1007/s11060-026-05554-y","DOIUrl":"https://doi.org/10.1007/s11060-026-05554-y","url":null,"abstract":"<p><strong>Purpose: </strong>Medulloblastoma (MB) is the most common malignant pediatric brain tumor and comprises molecularly and clinically distinct subgroups with highly variable outcomes. While survival rates exceed 80% in some subgroups, others remain associated with substantially poorer prognosis and increased risk of relapse. Current treatment includes surgery, radiation, and chemotherapy, which can result in significant long-term treatment-related morbidity. These challenges highlight the need to identify novel biomarkers and potential therapeutic targets to improve risk stratification and enable more tailored treatment approaches. The Traf2- and Nck-interacting kinase (TNIK) is a regulator of Wnt/β-catenin signaling and has been implicated in the progression of several cancers, but its role in MB remains unclear.</p><p><strong>Methods: </strong>TNIK expression was evaluated using publicly available MB transcriptomic datasets, mass spectrometry based proteomic data, and immunohistochemical analysis of a MB tissue microarray. Associations between TNIK expression, molecular subgroups, overall survival, and established prognostic markers were assessed.</p><p><strong>Results: </strong>TNIK expression was significantly enriched in Group 3 and Group 4 MBs compared to WNT and SHH subgroups. Survival analyses demonstrated distinct, subgroup-specific prognostic effects: high TNIK expression predicted inferior overall survival in Group 4, while in SHH tumors high TNIK expression levels were associated with improved outcome. These observations were supported by proteomic profiling.</p><p><strong>Conclusion: </strong>These findings indicate a subgroup-specific role for TNIK in MB biology and suggest its potential utility as a prognostic biomarker, particularly in Group 4 MBs.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human neural organoid modeling of diffuse midline glioma captures the complexity of patient tumors.","authors":"Jack M Shireman, Elliot Xie, Connie S Lebakken, Sudarshawn Damodharan, Kailyn T Parham, William D Richards, Rintaro Hashizume, Christina Kendziorski, Mahua Dey","doi":"10.1007/s11060-026-05515-5","DOIUrl":"10.1007/s11060-026-05515-5","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13152894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases.","authors":"Anais Andrade, Monica Mureb, Nilay Karaman, Cindy Liu, Joshua K Sabari, Rajwanth R Veluswamy, Kenneth Bernstein, Bernadine R Donahue, Benjamin T Cooper, Douglas Kondziolka","doi":"10.1007/s11060-026-05547-x","DOIUrl":"https://doi.org/10.1007/s11060-026-05547-x","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"177 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}